Academician Xu Binghe: Just like a slight awn, creating a torch and becoming a positive, "Chinese wisdom" in the field of breast cancer leads the world trend

foreword

The global oncology practice is gradually entering the era of "precision medicine", and individualized and precise treatment has become the hot spot and focus of breast cancer.

Expert Profile

Academician Xu Binghe

• Academician of Chinese Academy of Engineering, medical oncology expert

• Tenured professor and doctoral supervisor of Peking Union Medical College

• Former Director of the Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences

• The current director of the National New Drug (Anti-Tumor) Clinical Research Center

• Chairman of the Breast Cancer Expert Committee of the National Cancer Center for Quality Control

• Chairman of the National Expert Committee on Clinical Monitoring of Antineoplastic Drugs and Head of the Breast Group

• Chairman of the Professional Committee of Clinical Research on Cancer Drugs of China Anti-Cancer Association

• Honorary Chairman of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association

• Vice President of Internal Medicine Branch of Chinese Medical Doctor Association

• Chairman of Beijing Breast Disease Prevention and Control Society

• He has won the second prize of the National Science and Technology Progress Award, the National Innovation Award, the Ho Leung Ho Lee Foundation Science and Technology Progress Award and other awards as the first completer

  
  

Follow and catch up, break through and innovate

"Chinese Wisdom" Changes Breast Cancer Clinical Practice

China's research in the field of breast cancer has developed rapidly in the past ten years, from initial follow-up, to gradual catch-up, to breakthrough

In the field of triple-negative breast cancer, academic papers published by Chinese experts also have a place on the world stage, influencing clinical practice

In addition, in the field of HR-positive breast cancer, Chinese scholars have also done a lot of research, and I think the most important one is the DAWNA-1 study, which is the first domestic CDK4/6 inhibitor Dalcelix combined with fulvestrant in the treatment of the past.

In many fields such as immunotherapy and immune microenvironment, many domestic experts are also actively exploring, and have made great breakthroughs and progress

China and Europe double batch, creating a precedent

"Chinese Wisdom" sings on the international stage

HLX02-BC01 is a randomized, double-blind, international multi-center Phase III clinical study conducted simultaneously in 89 centers in China, the Philippines, Poland, and Ukraine, aiming to evaluate domestic trastuzumab ( ^Hanquyou® ) Efficacy, safety, and immunogenicity of trastuzumab and original investigational trastuzumab in patients with HER2-positive recurrent and metastatic breast cancer who have not received systemic therapy

Keep improving, collaborative innovation

"China Wisdom" leads the new direction of drug research and development

Precision therapy is one of the research directions of breast cancer treatment.

Second, more translational research should be carried out, and after the discovery of innovative targets, we should cooperate with pharmaceutical companies to develop targeted drugs as soon as possible
.

In addition, consideration should also be given to how the results of the research can be translated into clinical practice as soon as possible
.

It is necessary to cooperate with clinicians, experienced researchers and research institutions to design, implement, analyze, and summarize the clinical research, and finally bring the new drug to the market successfully
.

In addition, we must pay attention to the cutting-edge research trends in the world, strengthen communication between pharmaceutical personnel, scientific researchers and clinical staff, and CRO companies, so as to have a more comprehensive understanding of the cutting-edge progress in the field, strengthen collaboration, and jointly promote new drug research and development, and grasp the global new drug research and development.
dynamics and direction
.

Academician Xu Binghe said that he expected to strengthen cooperation in various fields, truly launch China's original new drugs, apply them in clinical practice, and lead the world in breast cancer diagnosis and treatment
.

Edit: Uni

Reviewer: Academician Xu Binghe

Typesetting: Uni

Execution: Uni